XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
PSUs
Class A Common Stock
Class A Common Stock
PSUs
Additional Paid-In Capital
Additional Paid-In Capital
PSUs
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2023 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2023 $ 178,427                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 2,867                
Series A preferred stock , ending balance (in shares) at Mar. 31, 2024 175,000                
Series A preferred stock , ending balance at Mar. 31, 2024 $ 181,294                
Beginning balance (in shares) at Dec. 31, 2023     115,425,000            
Beginning balance at Dec. 31, 2023 1,067,701   $ 1,154   $ 1,808,121   $ (1,257) $ (719,194) $ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 18,786       18,786        
Restricted stock units vested, net of shares withheld for taxes (in shares)     469,000            
Restricted stock units vested, net of shares withheld for taxes (9,770)   $ 5   (9,775)        
Exercise of stock options (in shares)     96,000            
Exercise of stock options 1,059   $ 1   1,058        
Performance stock units vested, net of shares withheld for taxes (in shares)       205,000          
Performance stock units vested, net of shares withheld for taxes   $ (4,564)   $ 2   $ (4,566)      
Foreign currency translation adjustment (51)           (51)    
Net loss attributable to common shareholders of Evolent Health, Inc. (25,225)       (7,945)     (17,280)  
Ending balance (in shares) at Mar. 31, 2024     116,195,000            
Ending balance at Mar. 31, 2024 $ 1,047,936   $ 1,162   1,805,679   (1,308) (736,474) (21,123)
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2024 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2024 $ 190,173                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 3,055                
Series A preferred stock , ending balance (in shares) at Mar. 31, 2025 175,000                
Series A preferred stock , ending balance at Mar. 31, 2025 $ 193,228                
Beginning balance (in shares) at Dec. 31, 2024 116,575,773   116,576,000            
Beginning balance at Dec. 31, 2024 $ 1,001,259   $ 1,166   1,803,786   (1,753) (780,817) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 11,081       11,081        
Restricted stock units vested, net of shares withheld for taxes (in shares)     510,000            
Restricted stock units vested, net of shares withheld for taxes (2,771)   $ 5   (2,776)        
Performance stock units vested, net of shares withheld for taxes (in shares)       312,000          
Performance stock units vested, net of shares withheld for taxes   $ (1,822)   $ 3   $ (1,825)      
Foreign currency translation adjustment 24           24    
Net loss attributable to common shareholders of Evolent Health, Inc. $ (72,250)       (7,632)     (64,618)  
Ending balance (in shares) at Mar. 31, 2025 117,397,804   117,398,000            
Ending balance at Mar. 31, 2025 $ 935,521   $ 1,174   $ 1,802,634   $ (1,729) $ (845,435) $ (21,123)